BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia

Inclusion Criteria:

* Patients with Philadelphia chromosome positive, chronic, accelerated or blast phase BML or ALL.
* Patients must have primary or acquired hematologic resistance to imatinib mesylate or have intolerance of imatinib mesylate.
* Men and women, 14 years of age or older.
* Adequate renal function.
* Adequate hepatic function.
* Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 1 month before and at least 3 months after the study in such a manner that the risk of pregnancy is minimized.

Exclusion Criteria:

* Patients who are eligible and willing to undergo transplantation during the screening period.
* Women who are pregnant or breastfeeding.
* A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy.
* Uncontrolled or significant cardiovascular disease.
* Medications that increase bleeding risk.
* Medications that change heart rhythms.
* Dementia or altered mental status that would prohibit the understanding of rendering of informed consent.
* History of significant bleeding disorder or unrelated to CML.
* Evidence of organ dysfunction or digestive dysfunction that would prevent administration of study therapy.
* Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.